Literature DB >> 11139316

Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.

G M Kraehn1, J Utikal, M Udart, K M Greulich, G Bezold, P Kaskel, U Leiter, R U Peter.   

Abstract

Amplification and overexpression of the c-myc gene have been associated with neoplastic transformation in a plethora of malignant tumours. We applied interphase fluorescence in situ hybridization (FISH) with a locus-specific probe for the c-myc gene (8q24) in combination with a corresponding chromosome 8 alpha-satellite probe to evaluate genetic alterations in 8 primary melanomas and 33 advanced melanomas and compared it to 12 melanocytic nevi, 7 safety margins and 2 cases of normal skin. Additionally, in metaphase spreads of 7 melanoma cell lines a whole chromosome 8 paint probe was used. We investigated the functionality of the c-myc gene by detecting c-myc RNA expression with RT-PCR and c-myc protein by immunohistochemistry. 4/8 primary melanomas and 11/33 melanoma metastases showed additional c-myc signals relative to the centromere of chromosome 8 copy number. None of the nevi, safety margins or normal skin samples demonstrated this gain. In 2/7 melanoma cell lines (C32 and WM 266-4) isochromosome 8q formation with a relative gain of c-myc copies and a loss of 8p was observed. The highest c-myc gene expression compared to GAPDH was found in melanoma metastases (17.5%). Nevi (6.6%) and primary melanomas (5.0%) expressed the c-myc gene on a lower level. 72.7% of the patients with c-myc extra copies had visceral melanoma metastases (UICC IV), patients without c-myc gain in 35.0% only. The collective with additional c-myc copies also expressed the gene on a significantly higher level. These results indicate that a c-myc gain in relation to the centromere 8 copy number might be associated with advanced cutaneous melanoma. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139316      PMCID: PMC2363612          DOI: 10.1054/bjoc.2000.1535

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Trends in sun exposure knowledge, attitudes, and behaviors: 1986 to 1996.

Authors:  J K Robinson; D S Rigel; R A Amonette
Journal:  J Am Acad Dermatol       Date:  1997-08       Impact factor: 11.527

2.  Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis.

Authors:  K Sisley; I G Rennie; M A Parsons; R Jacques; D W Hammond; S M Bell; A M Potter; R C Rees
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

3.  Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas.

Authors:  R Bergman; M Lurie; H Kerner; S Kilim; R Friedman-Birnbaum
Journal:  J Cutan Pathol       Date:  1997-04       Impact factor: 1.587

4.  Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas.

Authors:  S Ghazvini; D H Char; S Kroll; F M Waldman; D Pinkel
Journal:  Cancer Genet Cytogenet       Date:  1996-09

5.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

Authors:  R B Jenkins; J Qian; M M Lieber; D G Bostwick
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

6.  C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity.

Authors:  R Grover; D A Ross; P I Richman; B Robinson; G D Wilson
Journal:  Eur J Surg Oncol       Date:  1996-08       Impact factor: 4.424

7.  Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics.

Authors:  D W Visscher; T Wallis; S Awussah; A Mohamed; J D Crissman
Journal:  Genes Chromosomes Cancer       Date:  1997-01       Impact factor: 5.006

Review 8.  The c-myc oncogene in tumor progression.

Authors:  S J Garte
Journal:  Crit Rev Oncog       Date:  1993

9.  Cytogenetic findings in 21 malignant melanomas.

Authors:  Y Y Ozisik; A M Meloni; O Altungoz; A Peier; C Karakousis; S P Leong; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1994-10

Review 10.  The multistep nature of cancer.

Authors:  B Vogelstein; K W Kinzler
Journal:  Trends Genet       Date:  1993-04       Impact factor: 11.639

View more
  42 in total

Review 1.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

2.  Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma.

Authors:  Denitsa Koynova; Ekaterina Jordanova; Nicole Kukutsch; Pieter van der Velden; Draga Toncheva; Nelleke Gruis
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-15       Impact factor: 4.553

3.  A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.

Authors:  Ling-Yuan Kong; Mohamed K Abou-Ghazal; Jun Wei; Arup Chakraborty; Wei Sun; Wei Qiao; Gregory N Fuller; Izabela Fokt; Elizabeth A Grimm; Robert J Schmittling; Gary E Archer; John H Sampson; Waldemar Priebe; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

4.  Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.

Authors:  Arvind M Venkatesan; Rajesh Vyas; Alec K Gramann; Karen Dresser; Sharvari Gujja; Sanchita Bhatnagar; Sagar Chhangawala; Camilla Borges Ferreira Gomes; Hualin Simon Xi; Christine G Lian; Yariv Houvras; Yvonne J K Edwards; April Deng; Michael Green; Craig J Ceol
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

5.  Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.

Authors:  Marianna Avitabile; Mariangela Succoio; Alessandro Testori; Antonella Cardinale; Zalman Vaksman; Vito Alessandro Lasorsa; Sueva Cantalupo; Matteo Esposito; Flora Cimmino; Annalaura Montella; Daniela Formicola; Jan Koster; Virginia Andreotti; Paola Ghiorzo; Maria Fiammetta Romano; Stefania Staibano; Massimiliano Scalvenzi; Fabrizio Ayala; Hakon Hakonarson; Maria Valeria Corrias; Marcella Devoto; Matthew H Law; Mark M Iles; Kevin Brown; Sharon Diskin; Nicola Zambrano; Achille Iolascon; Mario Capasso
Journal:  Carcinogenesis       Date:  2020-05-14       Impact factor: 4.944

6.  The RING domain in the anti-apoptotic protein XIAP stabilizes c-Myc protein and preserves anchorage-independent growth of bladder cancer cells.

Authors:  Guosong Jiang; Chao Huang; Xin Liao; Jingxia Li; Xue-Ru Wu; Fuqing Zeng; Chuanshu Huang
Journal:  J Biol Chem       Date:  2019-02-28       Impact factor: 5.157

Review 7.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

8.  Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.

Authors:  Guo Chen; Nitin Chakravarti; Kimberly Aardalen; Alexander J Lazar; Michael T Tetzlaff; Bradley Wubbenhorst; Sang-Bae Kim; Scott Kopetz; Alicia A Ledoux; Y N Vashisht Gopal; Cristiano Goncalves Pereira; Wanleng Deng; Ju-Seog Lee; Katherine L Nathanson; Kenneth D Aldape; Victor G Prieto; Darrin Stuart; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

9.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

10.  Genetics of uveal melanoma and cutaneous melanoma: two of a kind?

Authors:  Thomas van den Bosch; Emine Kilic; Dion Paridaens; Annelies de Klein
Journal:  Dermatol Res Pract       Date:  2010-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.